Letrozol-ratiopharm® 2,5 mg

Description

Side effects

• Generally, adverse reactions were mild to moderately severe and mainly related to suppression of estrogen synthesis.
• Determination of the frequency of adverse reactions: very frequent ( >10%), frequent (1-10%), sometimes (0.1-1%), rarely (0.01-0.1%), very rare (<0.01%), including isolated reports
• Digestive system: often – nausea, vomiting, dyspepsia, constipation, diarrhoea; sometimes – abdominal pain, stomatitis, dry mouth, increased activity of liver enzymes.
• Nervous system disorders: often – headache, dizziness, depression; sometimes – anxiety, nervousness, irritability, drowsiness, insomnia, memory impairment, dysesthesia, paresthesia, hypoesthesia, episodes of cerebral circulation disorders.
• Hematopoiesis: sometimes – leukopenia.
• Cardiovascular system: sometimes – palpitations, tachycardia, thrombophlebitis of superficial and deep veins, BP increase, CHD (angina pectoris, myocardial infarction, heart failure), thromboembolism; rarely – pulmonary embolism, arterial thrombosis, stroke.
• Respiratory system: sometimes – dyspnoea, cough.
• Dermatological reactions: often – alopecia, increased sweating, skin rash (including erythematous, maculo-papular, vesicular rash, psoriasis-like rashes); sometimes – itching, dry skin, urticaria; very rarely – angioedema, anaphylactic reactions.
• Musculoskeletal system: very often – arthralgia; often – myalgia, bone pain, osteoporosis, bone fractures, sometimes – arthritis.
• Sensory organs: sometimes – cataract, eye irritation, blurred vision, taste disturbance.
• Urinary system: sometimes – increased urination, urinary tract infections.
• Reproductive system: sometimes – vaginal bleeding, vaginal discharge, vaginal dryness, pain in the mammary glands.
• Metabolism: often – increase in body weight, hypercholesterolaemia, anorexia, increased appetite; sometimes – decrease in body weight, thirst.
• Other: very often – hot flashes (hot flashes); often – increased fatigue, asthenia, malaise, peripheral edema; sometimes – hyperthermia (pyrexia), dry mucous membranes, generalised oedema, pain in tumour foci.